Why the study?
Pre-existing immunity and immune responses to AAV and transgenes cause safety concerns and risk rendering subsequent injections ineffective.
Design
Review
Authors
Loading...
Immune responses may limit AAV gene therapy to single use; leaves open strategies for safe re-dosing.
Key points are not available for this paper at this time.
Egorova et al. (2025) studied this question.
Synapse has enriched 5 closely related papers on similar clinical questions. Consider them for comparative context: